Search

Veracyte Inc

Closed

SectorHealthcare

56.48 -2.22

Overview

Share price change

24h

Current

Min

56.04

Max

57.91

Key metrics

By Trading Economics

Income

-20M

29M

Sales

-1.6M

139M

P/E

Sector Avg

54.533

62.58

EPS

0.52

Profit margin

20.642

Employees

755

EBITDA

-11M

35M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+1.94% upside

Dividends

By Acuity

Next Earnings

30 Jul 2026

Market Stats

By TradingEconomics

Market Cap

1.9B

4.6B

Previous open

58.7

Previous close

56.48

News Sentiment

By Acuity

50%

50%

163 / 340 Healthcare

Veracyte Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Jul 2026, 22:16 UTC

Correlated Moves

Veracyte Inc shares declined during after-market hours, reflecting broader weakness in the biotechnology sector. The stock shifted toward the lower end of its one-month trading range.

22 Jul 2026, 20:13 UTC

Correlated Moves

Veracyte Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21 Jul 2026, 17:16 UTC

Correlated Moves

Veracyte Inc shares are higher today, recovering after three days of declines. The stock is now above its 20-day moving average.

20 Jul 2026, 20:01 UTC

Correlated Moves

Veracyte Inc shares declined sharply today, marking three consecutive lower sessions amid broader market weakness and heightened volatility related to geopolitical tensions.

Peer Comparison

Price change

Veracyte Inc Forecast

Price Target

By TipRanks

1.94% upside

12 Months Forecast

Average 59 USD  1.94%

High 70 USD

Low 47 USD

Based on 10 Wall Street analysts offering 12 month price targets forVeracyte Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

8

Buy

1

Hold

1

Sell

Sentiment

By Acuity

163 / 340 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
help-icon Live chat